Cytodyn Inc (CYDY)

[HyGro]

LL FAILED the CD12 trial -- missed ALL endpoints. No amount of post-hoc data dredging will change that. In fact even the 62 critical patients with the "82%" was NOT statistically significant when using the appropriate statistical analysis -- not NPs manipulations. The trial was recruited properly -- CD12 average 58 years old for BOTH the treatment and placebo arm. The critical subgroup was NOT designed for an analysis or they would have designed for the analysis in the protocol, stratified the sample and had sufficient size for an viable analysis -- THEY DIDN'T so it has no validity as a trial analysis.